Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone.
Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone.
复制标题
用重组人生长激素治疗幼年慢性关节炎的生长迟缓。
DOI：
--
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
P. Woo
中科院分区：
文献类型：
--
作者：
Da;M. Rooney;MA Preece;Barbara M. Ansell;P. Woo
客观化
目的：评价重组人生长激素(RhGH)对长期活动性幼年型慢性关节炎(JCA)患儿直线生长发育的影响。它们都是严重的生长迟缓，但有足够的GH分泌。
方法
监测身高速度一年后，第二年分别给予12IU/m2或24IU/m2的重组人生长激素治疗。在此期间，记录了疾病活动、药物治疗、饮食摄入和骨成熟以及线性生长。
结果
在治疗期间，几乎所有儿童的身高速度都有显著的提高。轻度到中度疾病活动的儿童比那些疾病非常活跃的儿童生长速度更快。多关节病患儿的疗效优于全身性JCA患儿。接受高剂量重组生长激素治疗的儿童生长发育显著高于低剂量治疗方案的儿童。骨成熟未超过实际年龄。
结论
我们的结论是，在治疗一年内，重组人生长激素显著增加了身高速度。然而，它对成年人最终身高的影响仍不清楚。因此，需要进行广泛的长期研究来评估这种昂贵治疗的风险受益率。
OBJECTIVE
To evaluate the effect of recombinant human growth hormone (rhGH) on the linear growth of children with persistently active juvenile chronic arthritis (JCA), most of whom were receiving steroid therapy. All of them were severely growth retarded, but had adequate GH secretion.
METHODS
After monitoring height velocity for one year, children were treated for the following year with either 12 IU/m2 or 24 IU/m2 of rhGH. During this period disease activity, drug treatment, dietary intake and bone maturation as well as linear growth were documented.
RESULTS
There was a significant increase in height velocity in almost all children during the treatment period. Children with mild to moderate disease activity grew at a better rate than those with very active disease. Children with polyarticular disease responded better than those with systemic JCA. Those children receiving high dose rhGH grew significantly more than those on the low dose regimen. Bone maturation did not exceed chronological age.
CONCLUSION
We conclude the rhGH significantly increases the height velocity during one year of treatment. However, its effect on ultimate adult height remains unknown. Thus extensive longterm studies are required to evaluate the risk benefit ratio of this costly treatment.